Skip to main content

Table 6 Summary of costs and benefits of afatinib vs PemCis - base-case analysis

From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

 

Afatinib

Pemetrexed-cisplatin

Incremental difference

Total cost (SG$)

93,958

78,731

15,227

 Cost of PF state

44,205

11,236

32,969

 Cost of PD state

49,548

67,401

−17,853

 Cost of AE

205

94

111

Total benefit

 QALYs

1.69

1.58

0.11

 LYs

2.59

2.45

0.14

 PFLYs

1.18

0.68

0.50

ICER (QALY)

–

–

137,648

ICER (LY)

–

–

109,172

  1. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, LY life year, PFLY progression-free life year, AE adverse event, PF progression-free, PD progressed disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us